证券时报社党委委员、社长助理朱丽：我国正从“医药大国”向“创新策源地”跨越

Core Insights - China has become the global leader in the number of innovative drugs under research, with one in three clinical-stage innovative drugs originating from China, marking a significant transition from being a "big pharmaceutical country" to an "innovation source" [1] - The internationalization of Chinese pharmaceutical companies is highlighted, showcasing their ability to provide more treatment options for global patients, thus reshaping the global industry landscape [1] - In the first half of 2025, over 40% of the upfront payments exceeding $50 million from multinational pharmaceutical companies (MNCs) for licensing deals originated from China, indicating China's upgraded role from a "participant" to a "co-builder of rules" in the global pharmaceutical market [1] - During the same period, China saw over 50 overseas licensing transactions for innovative drugs, totaling $48.4 billion, approaching the total level of 2024, reflecting the success of China's "innovation-driven development" strategy [1]